3rd Annual Global Medical Affairs Summit

2 - 3 June 2021 I ONLINE

PAST SPEAKERS

SEE THE PREVIOUS SPEAKERS & CASE STUDIES

Jolana SCHMIEDL

Associate Director Medical Affairs

Inaam HAQ

Medical Director

Rafael BRAVO

Vice President Obesity, RWE & Publications in Global Medical Affairs

Alex MEHUYS

Medical Director EMEA Hematology

Gareth

WORTHINGTON

Director, Global Scientific Content, Oncology Team Lead

CONFERENCE TOPICS 2021

LOOK AT THE TOPICS THAT WERE DISCUSSED

  • How do the new EU MedTechs impact medical affairs?
  • What are the best ways to integrate the e-medical tactics in medical affairs?
  • What are the innovative ways of mining and interpreting data?
  • The RWE as main decision-making instrument in drug development and commercialisation
  • How is COVID-19 affecting the activity of MSLs in companies: Ways of adaptation?
  • Medical affairs as a key instrument in bridging the gap between R&D and Commercial
  • Collaboration between medical affairs and tech innovators as a way to improve engagement with patients (by using innovative products and technologies)

Designed for

Members of board, C-level, Senior Vice Presidents, Vice Presidents, Directors, and Heads of departments from pharma industry involved in:

  • Medical Science Liaisons (MSL)
  • Medical Information
  • Medical Writing
  • Medical and Scientific Communication
  • Scientific Affairs
  • Real World Evidence
  • Commercial Excellence
  • Market Access
  • KOL/Thought Leader Relations/Engagement
  • Clinical Affairs
  • Medical Review
  • Health Economics and Outcomes Research/HEOR
  • Product Launch
  • Patient Outcome
  • Patient Centricity
  • Digital Medical
  • Customer Value
  • Scientific Engagement
  • Scientific Partnerships
  • Commercial Operations
  • External Affairs
  • Medical Affairs Operations
  • Medical Strategy
  • Policy & Market Access
  • Portfolio Planning
  • Launch Management
  • Medical/Scientific/Patient Communications
  • Scientific Information

Jolana SCHMIEDL

Associate Director Medical Affairs

CASE STUDY / DAY 1

What Are the Most Effective Decision-Making Tools in Medical Affairs?

The role of medical affairs changed in last decade dramatically, from a supportive function to a strong and meaningful component of the pharmaceutical industry. This change is accompanied with different expectations and responsibilities for medical affairs in each level. The presentation will focus on one of the important tool the medical affairs can impact.

  • Why do we need RWE?
  • What makes RWE powerful?
  • What is the role of medical affairs in generating and handling with RWE?
CASE STUDY / DAY 1

Moving from Drug Manufacturer to Healthcare Enabler

Nike rarely advertises a single pair of sneakers, they discuss sports. Likewise pharma companies should embark of a path of discussing and providing healthcare solutions to the community rather than touting a new drug. We live in a world of information, and it is our duty to have a voice.

Gareth WORTHINGTON

Director, Global Scientific Content, Oncology Team Lead

Alex MEHUYS

Medical Director EMEA Hematology

CASE STUDY / DAY 2

Unlocking Customer Value Growth

The role of medical affairs has changed in the last 5 years and this change has increased dramatically due to the COVID-19 pandemic.

  • Medical affairs has evolved into a multi-functional role
  • Digitalisation is the main challenge
CASE STUDY / DAY 2

The Review of RWE and the Evolution of Its Usage in the Biopharmaceutical Industry

To describe the ongoing trends in the value of RWE to an expanding stakeholders group (payers, regulators, HCPs/patients, healthcare systems) and internally (e.g. R&D), the evolving framework in pharma, and the role of medical affairs should be in the present and future.

  • What is the evolving value of RWE to an expanding number of stakeholders?
  • Key focus areas for a successful RWE strategy in pharma
  • What is the role and value of medical affairs in the corporate RWE strategy?

Rafael BRAVO

Vice President Obesity, RWE & Publications in Global Medical Affairs

SPONSORS

The topics presented were interesting and I was able to take away some new ideas. I really liked hearing from other pharma companies

Country Medical and Regulatory Director Switzerland at AstraZeneca

STAY UPDATED FOR THE 2022 EDITION

Provide Us With Your Contact Details and Our Team Will Get Back to You With All the Updates Regarding the Upcoming Edition of This Event.